Clinical trials: Psychotic Symptoms
Schizophrenia
Risperidone Maintenance Treatment in Schizophrenia
This study set out to determine the duration of maintenance treatment with therapeutic risperidone dose in schizophrenia. In a multi-center, open label, randomized, controlled study design, patients with schizophrenia who were…
- Trial name
- NCT00848432
- Testing
- risperidone
- Where
- China
- Volunteers
- 404 people
- Sponsor
- Capital Medical University
Schizophrenia and Related Disorders
rTMS for Depressive, Positive and Negative Symptoms, and Physiological Indices of Schizophrenia Patients
Around 40% of schizophrenia patients present depressive symptoms, which are associated with elevated suicide and violence risk and poor prognosis and quality of life.
- Trial name
- NCT05671185
- Testing
- Repetitive Transcranial Magnetic Stimulation
- Where
- Taiwan
- Volunteers
- 180 people
- Sponsor
- National Taiwan University Hospital
Schizophrenia, Auditory Hallucination
Real-time fMRI Neurofeedback in Patients With Schizophrenia and Auditory Hallucinations
Neurofeedback intervention aimed to regulate the superior temporal gyrus (STG) activation and default mode network (DMN) connectivity as well as to reduce the auditory hallucinations (AH) schizophrenia patients with medication…
- Conditions
- Schizophrenia, Auditory Hallucination, Treatment-resistant Schizophrenia
- Trial name
- NCT05299749
- Testing
- stg-rt-fMRI-Neurofeeback
- Where
- United States
- Volunteers
- 104 people
- Sponsor
- Boston VA Research Institute, Inc.
Schizophrenia, Schizoaffective Disorder
Tocilizumab as Add-On Treatment For Residual Positive, Negative, and Cognitive Symptoms of Schizophrenia
Randomized, double-blind clinical trial of tocilizumab vs. placebo as add-on treatment for residual positive, negative, and cognitive symptoms in schizophrenia.
- Trial name
- NCT02034474
- Testing
- Tocilizumab
- Where
- United States
- Volunteers
- 59 people
- Sponsor
- New York State Psychiatric Institute
Depressive Disorder, Bipolar Disorder
Nonconvulsive Electrotherapy: a Proof-of-concept Trial
This study involves pilot testing of a modified version of a proven treatment for mental illness. The treatment, electroconvulsive therapy (ECT) is used to treat more than 100,000 Americans yearly.
- Conditions
- Depressive Disorder, Bipolar Disorder, Schizoaffective Disorder
- Trial name
- NCT01065597
- Testing
- Nonconvulsive electrotherapy
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- University of Maryland, College Park
Schizophrenia, Schizoaffective Disorder
A Study to Assess the Effects of RO6889450 (Ralmitaront) in Participants With Schizophrenia or Schizoaffective Disorder and Negative Symptoms
This study investigates the effects of RO6889450 on the negative symptoms associated with schizophrenia and schizoaffective disorder.
- Trial name
- NCT03669640
- Testing
- RO6889450
- Where
- 45 sites in United States, Japan and 2 more
- Volunteers
- 131 people
- Sponsor
- Hoffmann-La Roche
Schizophrenia, Schizoaffective Disorder
Naltrexone for Antipsychotic-Induced Weight Gain
This study is designed to look at the effects of naltrexone on weight loss in individuals treated with antipsychotic medications.
- Conditions
- Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder, Bipolar Disorder
- Trial name
- NTX (NCT01866098)
- Testing
- Naltrexone
- Where
- United States
- Volunteers
- 144 people
- Sponsor
- Yale University
Mental Health Issue (E.G., Depression, Psychosis, Personality Disorder, Substance Abuse)
Effectiveness of a Problem-solving Intervention for Common Adolescent Mental Health Problems in India
We will conduct a two-arm individually randomized controlled trial in six Government-run secondary schools in New Delhi. The targeted sample is 240 adolescents in grades 9-12 with persistent, elevated mental health difficulties…
- Trial name
- PRIDE (NCT03630471)
- Testing
- PRIDE 'Step 1' problem-solving intervention, Enhanced usual care
- Where
- India
- Volunteers
- 250 people
- Sponsor
- Sangath
Sleep Initiation and Maintenance Disorder; Elderly, Mental Disorder
A Long-Term Safety Study of Org 50081 (Esmirtazapine) in Elderly Outpatients With Chronic Primary Insomnia (176005/P05697/MK-8265-001)
The current study is a 52-week safety study in elderly outpatients with chronic primary insomnia randomized to treatment with 1.5 mg or 3.0 mg of esmirtazapine (Org 50081, SCH 900265, MK-8265) to investigate the safety and…
- Conditions
- Sleep Initiation and Maintenance Disorder; Elderly, Mental Disorder, Dyssomnias, Sleep Disorders
- Trial name
- Jade (NCT00561574)
- Testing
- Esmirtazapine
- Volunteers
- 259 people
- Sponsor
- Merck Sharp & Dohme LLC
Tardive Dyskinesia
Melatonin Treatment for Tardive Dyskinesia in Schizophrenia
This is a double-blind, randomized, placebo-controlled trial of melatonin as an add-on therapy to antipsychotics will be performed to examine the effects of melatonin on tardive dyskinesia symptoms and cognitive deficits in 120…
- Trial name
- NCT01391390
- Testing
- Melatonin
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Beijing HuiLongGuan Hospital
Agitation
Treating Acutely Agitated Patients With Asenapine Sublingual Tablets
Our proposal is to administer asenapine to patients who are clinically agitated and in need of immediate intervention. At present there are no controlled studies that we know of that explores the use of asenapine for this…
- Trial name
- NCT01400113
- Testing
- Asenapine
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- Unity Health Toronto
Mental Disorder, Schizophrenia Diagnosis
Validation of a VOICE MAnagement Program in Schizophrenia VVoice MAPS
Approximately 25-50% of patients with schizophrenia experience treatment-resistant Auditory Verbal Hallucinations (AVHs), which contribute to the development of associated psychopathological disorders (e.g., anxiety, depression…
- Trial name
- PROGEVs (NCT07266376)
- Testing
- Integrative group therapy
- Where
- Guadeloupe
- Volunteers
- 116 people
- Sponsor
- Centre Hospitalier Universitaire de la Guadeloupe
Schizophrenia, Negative Symptoms of Schizophrenia
Berberine in Treating Negative Symptoms of Schizophrenia: Clinical Efficacy and Mechanisms
"Negative" symptoms are a major challenge for people with schizophrenia (SZ) and are a key reason why they struggle with everyday functioning.
- Trial name
- NCT07356765
- Testing
- Berberine
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Tianjin Anding Hospital
Overweight and Obesity, Metabolic Cardiovascular Syndrome
The Effects of Psyllium Seed on Body Weight and Metabolic Syndrome Indicators in Patients with Schizophrenia
The research employs a quasi-experimental design, aiming to enroll 24 hospitalized patients with schizophrenia from 2hospitals in the central region, guided by G Power calculations.
- Conditions
- Overweight and Obesity, Metabolic Cardiovascular Syndrome, Schizophrenia, Disorganized
- Trial name
- NCT06789471
- Testing
- psyllium husk
- Where
- Taiwan
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Ru-Shin Zhang
Schizophenia Disorder
Theta- and Alpha-Tuned Meditation for Negative Symptoms in Schizophrenia
This study done at the psychiatrics hospital of the cross Lebanon examined whether guided meditation combined with special sound stimulation (binaural beats) could help reduce negative symptoms of schizophrenia, such as low…
- Trial name
- ALPHATH-SCZ (NCT07437365)
- Testing
- Alpha binaural beats, Theta binaural beats
- Where
- Lebanon
- Volunteers
- 90 people
- Sponsor
- Psychiatric Hospital of the Cross
Schizophrenia, Central Obesity
Effect of Dietary Fiber Supplement on the Intestinal Microbiota Among Schizophrenia Patients
Background There has been much interest in the relationship between the types of gut microbiota and the development of obesity in recent years.
- Trial name
- NCT03552237
- Testing
- dietary fiber
- Volunteers
- 40 people
- Sponsor
- TsaoTun Psychiatric Center, Department of Health, Taiwan
Schizophrenia, Schizoaffective Disorder
Add-on HD Hf-tRNS Over Bilateral DLPFC for Treating Patients With Schizophrenia
The study aimed to investigate the effects of high-definition transcranial random noise stimulation over bilateral prefrontal cortex on psychopathological symptoms, other clinical outcomes, autonomic functioning ,and brain…
- Conditions
- Schizophrenia, Schizoaffective Disorder, Psychotic Symptoms, Neurocognitive Dysfunction
- Trial name
- NCT04038788
- Testing
- HD hf-tRNS
- Where
- Taiwan
- Volunteers
- 36 people
- Sponsor
- Tri-Service General Hospital (TSGH)
Schizophrenia
Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Residual Schizophrenia
The objectives of this 12-week study are to evaluate the efficacy, safety, and tolerability of AVP-786 as an adjunctive treatment compared with placebo in patients with residual schizophrenia.
- Trial name
- NCT02477670
- Testing
- AVP-786
- Where
- 17 sites in United States
- Volunteers
- 145 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Schizophrenia
Bilateral Repetitive Transcranial Magnetic Stimulation for Auditory Hallucinations Original Study
This trial is designed to determine if administering repetitive transcranial magnetic stimulation (rTMS) simultaneously to two sites in the temporal lobes, one on the left and one on the right, produces greater improvements in…
- Trial name
- NCT00567281
- Testing
- Magstim Rapid 2 system triggering Magstim Super Rapid system, Magstim Rapid-2 system triggering Magstim Super Rapid system
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Yale University
Schizophrenia
An Extension Study to Assess Long-Term Safety and Tolerability of Adjunctive KarXT in Subjects With Inadequately Controlled Symptoms of Schizophrenia
This is a Phase 3, multicenter, 52-week, outpatient, open-label extension (OLE) study to evaluate the long-term safety and tolerability of adjunctive KarXT in subjects with schizophrenia with an inadequate response to their…
- Trial name
- NCT05304767
- Testing
- Xanomeline and Trospium Chloride Capsules
- Where
- 94 sites in United States, Bulgaria and 2 more
- Volunteers
- 290 people
- Sponsor
- Karuna Therapeutics, Inc., a Bristol Myers Squibb company
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.